For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230831:nRSe9717Ka&default-theme=true
RNS Number : 9717K Bank of America Merrill Lynch 31 August 2023
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader BofA Securities, Inc.
Company dealt in HORIZON THERAPEUTICS PLC
Class of relevant security to which the Common - IE00BQPVQZ61
dealings being disclosed relate(Note 1)
Date of dealing 30/08/2023
BofA Securities, Inc.
Company dealt in
HORIZON THERAPEUTICS PLC
Class of relevant security to which the
dealings being disclosed relate(Note 1)
Common - IE00BQPVQZ61
Date of dealing
30/08/2023
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant
security
dealt in (Note 2)
Class of relevant security: Common IE00BQPVQZ61
Long Short
Number % Number %
(1) Relevant securities 327,562 0.143% 113,256 0.049%
(2) Derivatives (other than options): 170,344 0.074% 75,240 0.033%
(3) Options and agreements to purchase/sell: 50,000 0.022% 19,500 0.009%
Total 547,906 0.239% 207,996 0.091%
327,562
0.143%
113,256
0.049%
(2) Derivatives (other than options):
170,344
0.074%
75,240
0.033%
(3) Options and agreements to purchase/sell:
50,000
0.022%
19,500
0.009%
Total
547,906
0.239%
207,996
0.091%
(b) Interests and short positions in relevant securities of the company, other
than the
class dealt in (Note 2)
Class of relevant security:
Long Short
Number % Number %
(1) Relevant securities 0 0% 0 0%
(2) Derivatives (other than options): 0 0% 0 0%
(3) Options and agreements to purchase/sell: 0 0% 0 0%
Total 0 0% 0 0%
0
0%
0
0%
(2) Derivatives (other than options):
0
0%
0
0%
(3) Options and agreements to purchase/sell:
0
0%
0
0%
Total
0
0%
0
0%
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 4)
Purchase 8,487 112.82 USD
Purchase 2,600 113 USD
Purchase 8,500 113.02 USD
Purchase 500 113.03 USD
Purchase 100 113.035 USD
Purchase 4,400 113.04 USD
Purchase 100 113.088 USD
Purchase 1,100 113.09 USD
Purchase 700 113.095 USD
Purchase 3,100 113.1 USD
Purchase 7 113.105 USD
Purchase 2,393 113.11 USD
Purchase 45 112.82 USD
Purchase 45,000 112.9 USD
Purchase 45,000 113.125 USD
Purchase/sale Number of relevant securities Price per unit (Note 4)
Sale 1,358 112.79 USD
Sale 400 112.793 USD
Sale 100 112.795 USD
Sale 10,794 112.8 USD
Sale 25 112.804 USD
Sale 443 112.805 USD
Sale 25 112.806 USD
Sale 40 112.808 USD
Sale 48 112.809 USD
Sale 4,566 112.81 USD
Sale 42 112.811 USD
Sale 43 112.812 USD
Sale 244 112.813 USD
Sale 23 112.814 USD
Sale 700 112.815 USD
Sale 45 112.816 USD
Sale 30 112.817 USD
Sale 2,877 112.82 USD
Sale 22 112.823 USD
Sale 121 112.825 USD
Sale 23 112.827 USD
Sale 22 112.828 USD
Sale 3,035 112.83 USD
Sale 24 112.831 USD
Sale 43 112.833 USD
Sale 23 112.834 USD
Sale 400 112.835 USD
Sale 7,889 112.84 USD
Sale 25 112.843 USD
Sale 20 112.844 USD
Sale 300 112.845 USD
Sale 84 112.846 USD
Sale 44 112.847 USD
Sale 79 112.849 USD
Sale 1,745 112.85 USD
Sale 22 112.852 USD
Sale 48 112.853 USD
Sale 200 112.855 USD
Sale 66 112.856 USD
Sale 44 112.858 USD
Sale 3,550 112.86 USD
Sale 23 112.861 USD
Sale 59 112.862 USD
Sale 656 112.87 USD
Sale 25 112.871 USD
Sale 20 112.872 USD
Sale 39 112.875 USD
Sale 20 112.877 USD
Sale 400 112.88 USD
Sale 24 112.882 USD
Sale 27 112.884 USD
Sale 23 112.889 USD
Sale 1,744 112.89 USD
Sale 80 112.891 USD
Sale 33 112.892 USD
Sale 41 112.893 USD
Sale 20 112.894 USD
Sale 318 112.895 USD
Sale 22 112.896 USD
Sale 1,777 112.9 USD
Sale 144 112.91 USD
Sale 3 112.92 USD
Sale 3 112.97 USD
Sale 4,594 113 USD
Sale 6 113.01 USD
Sale 300 113.025 USD
Sale 100 113.043 USD
Sale 3 113.05 USD
Sale 3 113.06 USD
Sale 6 113.17 USD
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD
(Note 5) (Note 6)
(Note 4)
Swaps Reducing a long position 2,042 112.82 USD
Swaps Reducing a long position 6,237 112.82 USD
Swaps Reducing a long position 208 112.82 USD
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc Expiry date Option money paid/ received per unit (Note 4)
N/A N/A N/A N/A N/A N/A N/A
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option
unit (Note 4)
N/A N/A N/A
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Nature or transaction Details Price per unit
(Note 7)
(if applicable) (Note 4)
N/A N/A N/A
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights
or future acquisition or disposal of any relevant securities to which any
derivative
referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 38.5(b) attached? (Note 8) No
Date of disclosure 31/08/2023
Contact name Frank Lui
Telephone number +44207 996 6418
Name of offeree/offeror with which connected AMGEN INC
Nature of connection (Note 9) Advisor to - AMGEN INC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ITPEANPFDSNDEEA